SYNERGY PHARMACEUTICALS, INC. (SGYP) is a publicly traded company in the Unknown sector. Across all available filings, 10 corporate insiders have executed 55 transactions totaling $47.2M, demonstrating a bearish sentiment with -$43.5M in net insider flow. The most recent transaction on Aug 15, 2018 involved a transaction of 150,000 shares valued at $180.0K.
No significant insider buying has been recorded for SGYP in the recent period.
No significant insider selling has been recorded for SGYP in the recent period.
Based on recent SEC filings, insider sentiment for SGYP is bearish with an Insider Alignment Score of 4/100 and a net flow of -$43.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at SYNERGY PHARMACEUTICALS, INC. (SGYP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 10 insiders are actively trading SGYP stock, having executed 55 transactions in the past 90 days. The most active insider is &. Co. Inc. Paulson (Executive), who has made 8 transactions totaling $45.2M.
Get notified when executives and directors at SGYP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 15, 2018 | K. Spigelman Melvin | Executive | Option Exercise | 150,000 | $1.20 | $180.0K | |
| Aug 15, 2018 | K. Spigelman Melvin | Executive | Payment | 101,695 | $N/A | $0 | |
| Jul 4, 2018 | P. Brancaccio John | Executive | Payment | 13,896 | $N/A | $0 | |
| Jul 4, 2018 | P. Brancaccio John | Executive | Option Exercise | 50,023 | $0.50 | $25.0K | |
| Jul 3, 2018 | Adams Thomas Phd | Executive | Payment | 27,785 | $N/A | $0 | |
| Jul 3, 2018 | Adams Thomas Phd | Executive | Option Exercise | 100,023 | $0.50 | $50.0K | |
| Jun 15, 2018 | S. Jacob Gary | Executive | Payment | 150,246 | $N/A | $0 | |
| Jun 15, 2018 | S. Jacob Gary | Executive | Option Exercise | 474,961 | $0.50 | $237.5K | |
| Jun 15, 2018 | S. Jacob Gary | Executive | Payment | 131,934 | $N/A | $0 | |
| Apr 2, 2018 | P. Brancaccio John | Executive | Option Exercise | 50,000 | $0.50 | $25.0K | |
| Nov 10, 2017 | Co. Inc. Paulson &. | Executive | Sale | 8,750,000 | $2.82 | $24.7M | Large |
| Aug 7, 2017 | Co. Inc. Paulson &. | Executive | Sale | 26,200 | $3.77 | $98.8K | |
| Aug 7, 2017 | Co. Inc. Paulson &. | Executive | Sale | 87 | $3.78 | $329 | |
| May 26, 2017 | S. Jacob Gary | Executive | Purchase | 5,680 | $3.52 | $20.0K | |
| May 26, 2017 | P. Brancaccio John | Executive | Purchase | 6,500 | $3.59 | $23.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 13 | $45.4M | 93.8% |
Purchase(P) | 18 | $1.9M | 3.9% |
Exercise(M) | 10 | $970.3K | 2.0% |
Award(A) | 9 | $155.6K | 0.3% |
Payment(F) | 5 | $0 | 0.0% |
Insider selling pressure at SYNERGY PHARMACEUTICALS, INC. has increased, with 10 insiders executing 55 transactions across all time. Total sales of $45.4M significantly outpace purchases of $1.9M, resulting in a net outflow of $43.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.